elev
lowdens
lipoprotein
cholesterol
ldlc
one
major
contributor
cardiovascular
heart
diseas
chd
lead
caus
death
worldwid
due
sever
side
effect
statin
altern
treatment
strategi
requir
statinintoler
patient
monoclon
antibodi
mab
target
proprotein
convertas
subtilisinkexin
type
shown
great
efficaci
ldlc
reduct
limit
approach
includ
need
multipl
inject
well
increas
cost
associ
patient
manag
engin
dnaencod
mab
dmab
target
altern
approach
proteinbas
lipidlow
therapeut
character
express
activ
singl
intramuscular
administr
mous
gener
express
vivo
day
correspond
substanti
decreas
nonhighdens
lipoprotein
cholesterol
nonhdlc
total
cholesterol
day
wildtyp
mice
repeat
administr
dmab
plasmid
led
increas
express
dmab
level
mgml
day
therapeut
may
provid
novel
simpl
less
frequent
costeffect
approach
reduc
ldlc
either
standalon
therapi
combin
ldllower
therapeut
synergist
effect
cardiovascular
diseas
common
caus
death
account
death
unit
state
million
death
global
elev
lowdens
lipoprotein
cholesterol
ldlc
found
one
major
contributor
atherosclerosi
cardiovascular
heart
diseas
chd
famili
hypercholesterolemia
fh
autosom
domin
disord
character
elev
total
cholesterol
primarili
ldlc
associ
prematur
cardiovascular
diseas
often
result
death
young
age
lipidlow
medic
ldl
apheresi
especi
statinintoler
patient
use
manag
famili
hypercholesterolemia
better
pharmacolog
therapeut
need
achiev
maintain
desir
target
ldlc
level
proprotein
convertas
secretori
mammalian
serin
proteas
induc
sitespecif
proteolyt
cleavag
protein
form
irrevers
posttransl
modif
lead
activ
inactiv
protein
growth
factor
receptor
hormon
transcript
factor
bacteri
toxin
viral
glycoprotein
major
implic
health
diseas
due
broad
biolog
role
sever
modul
inhibitor
proprotein
convertas
develop
hypercholesterolemia
proprotein
convertas
subtilisinkexin
type
inhibitor
viral
infect
furin
inhibitor
cancer
immunotherapi
furin
inhibitor
well
use
nonsteroid
male
contracept
inhibitor
serin
proteas
belong
famili
mammalian
proprotein
convertas
cleav
form
catalyt
inact
protein
proseg
remain
associ
complex
complex
interact
lowdens
lipoprotein
receptor
ldlr
lead
intern
degrad
decreas
ldlr
hepatocyt
surfac
result
decreas
clearanc
ldl
particl
circul
gainoffunct
gof
mutat
lead
higher
ldlc
level
report
associ
hypercholesterolemia
increas
risk
chd
lossoffunct
lof
mutat
hand
correl
decreas
ldlc
reduc
chd
risk
rare
case
sever
lof
mutat
produc
detect
protein
report
exhibit
ldlc
level
around
mgdl
interestingli
individu
identifi
without
neg
effect
individu
valid
therapeut
target
pharmacolog
intervent
inhibitor
emerg
novel
approach
treatment
dyslipidemia
primarili
use
highrisk
cardiovascular
patient
includ
famili
hypercholesterolemia
case
manag
ldlc
high
risk
plaqu
progress
peopl
statin
intoler
around
patient
treat
statin
exhibit
advers
side
effect
muscl
pain
weak
rhabdomyolysi
approach
inhibit
involv
monoclon
antibodi
small
interf
rna
sirna
antisens
oligonucleotid
adnectin
small
molecul
peptid
mimet
vaccin
current
two
us
food
drug
administr
fda
approv
inhibitor
alirocumab
regeneron
sanofi
evolocumab
amgen
fulli
human
monoclon
antibodi
mab
target
clinic
trial
highrisk
cardiovascular
patient
demonstr
efficaci
reduc
ldlc
clinic
trial
heterozyg
famili
hypercholesterolemia
patient
treatment
evolocumab
week
mgmonth
result
decreas
ldlc
level
patient
abl
reach
ldlc
goal
mgdl
odyssey
high
clinic
trial
famili
hypercholesterolemia
patient
treat
alirocumab
mg
everi
week
difficulttotreat
sever
famili
hypercholesterolemia
abl
reach
ldlc
goal
mgdl
moreov
alirocumab
administ
statintr
patient
achiev
significantli
greater
reduct
ldlc
doubl
dose
statin
receiv
addit
ezetimib
cost
major
limit
clinic
manag
highrisk
cardiovascular
patient
biolog
product
recombin
mab
complex
expens
manufactur
evolocumab
alirocumab
project
cost
around
per
year
per
patient
recent
analysi
costeffect
inhibitor
use
atherosclerot
cardiovascular
diseas
ascvd
patient
found
inhibitor
poorli
costeffect
reduct
price
need
reach
patient
willingnesstopay
threshold
lifeyear
qali
addit
high
cost
current
recombin
antibodi
requir
frequent
administr
inject
everi
week
develop
costeffect
longerliv
potent
pharmacolog
intervent
would
provid
avenu
make
therapeut
wide
avail
highrisk
cardiovascular
patient
compar
therapeut
approach
vivo
electropor
technolog
plasmid
dna
deliv
transient
integr
therefor
allow
repeat
administr
without
advers
consequ
furthermor
recombin
protein
therapi
approach
numer
repeat
administr
requir
gener
come
high
financi
cost
patient
dnaencod
mab
dmab
platform
possibl
administ
therapeut
repeatedli
without
face
challeng
preexist
immun
difficult
manufactur
process
high
cost
dmab
technolog
repres
new
approach
direct
vivo
product
biolog
activ
immunoglobulin
patient
nonperman
fashion
lowvoltag
electropermeabil
allow
robust
plasmid
dna
deliveri
tissu
deliv
plasmid
contain
encod
antibodi
sequenc
drive
transcript
vivo
translat
desir
protein
recent
report
describ
adapt
technolog
approach
specif
infecti
diseas
cancer
target
report
util
approach
vivo
chronic
diseas
therapi
develop
dmab
approach
figur
target
base
engin
plasmid
dna
encod
novel
mab
singl
insert
express
cassett
name
label
human
mous
respect
bear
human
mous
fc
region
vivo
plasmid
administr
use
electroporationenhanc
intramuscular
inject
perform
evalu
dmab
product
kinet
efficaci
inhibit
lipid
reduct
vivo
robust
product
dmab
began
within
day
administr
peak
level
antibodi
achiev
week
postinject
dmab
could
detect
sera
month
level
could
boost
addit
administr
vivoproduc
dmab
retain
abil
bind
target
increas
ldlr
detect
upon
vivo
administr
express
accompani
signific
reduct
nonhighdens
lipoprotein
cholesterol
nonhdlc
total
cholesterol
level
nude
mice
studi
observ
support
excit
proof
principl
studi
util
dmab
approach
treatment
dyslipidem
disord
mous
design
singl
link
heavyand
lightchain
cassett
express
singl
open
read
frame
heavyand
lightchain
gene
separ
previous
develop
cleavag
site
figur
provid
effici
protein
process
necessari
immunoglobulin
g
igg
product
vivo
cytomegaloviru
cmv
promot
vector
use
drive
express
antibodi
final
construct
design
hr
plasmid
transfect
cell
secret
antibodi
express
supernat
determin
ngml
figur
western
blotbind
studi
use
supernat
dmabtransfect
cell
show
specif
bind
human
mous
recombin
antigen
greater
bind
detect
human
figur
show
proper
bind
activ
antigen
fluoresc
microscopi
also
use
demonstr
express
cell
figur
show
strong
express
dmab
plasmidtransfect
control
cell
express
level
durat
dmab
evalu
wildtyp
nude
mice
wwwmoleculartherapyorg
jackson
laboratori
figur
plasmid
dna
mg
inject
intramuscularli
tibiali
anterior
muscl
follow
electropor
imep
mous
backbon
demonstr
high
express
long
durat
level
reach
maximum
mean
ngml
day
persist
week
blood
level
ngml
day
nude
mice
express
higher
reach
maximum
mean
ngml
day
express
persist
last
bleed
day
sequenti
administr
mous
dmab
day
result
continu
increas
dmab
express
level
reach
ngml
mg
dose
day
figur
highlight
sustain
dmab
express
long
period
improv
express
observ
dose
spread
severalweek
period
simplifi
administr
inhibit
determin
use
western
blot
analysi
ldlr
express
level
mous
liver
section
figur
mous
liver
harvest
day
ldlr
express
evalu
compar
human
mice
control
mice
western
blot
analysi
show
ldlr
express
level
significantli
higher
dmabtreat
mice
control
mice
elisa
protein
quantif
use
detect
presenc
dmab
liver
treat
mice
dmab
level
ngmg
tissu
figur
bind
western
blot
analysi
use
evalu
bind
dmab
serum
sampl
dmabtreat
untreat
mice
human
mous
protein
figur
incub
serum
sampl
blot
contain
recombin
mous
human
protein
sera
dmabtreat
mice
react
protein
sera
mice
furthermor
evalu
human
liver
cell
line
hr
transfect
cell
harvest
analyz
flow
cytometri
figur
signific
increas
ldlr
level
group
mean
fluoresc
intens
mfi
increas
control
group
dmabtreat
group
result
demonstr
function
efficaci
inhibit
protein
induc
ldlr
degrad
hepatocyt
lipidlow
capabl
evalu
wildtyp
nude
mice
figur
accur
calcul
lipid
reduct
treat
group
percentag
decreas
analyz
control
group
day
mice
signific
decreas
nonhdlc
detect
day
group
day
decreas
nonhdlc
group
total
cholesterol
reduct
also
observ
group
decreas
day
nude
mice
signific
reduct
nonhdlc
day
treat
reduct
persist
day
similar
reduct
total
cholesterol
persist
day
decreas
persist
reduct
nonhdlc
total
cholesterol
mous
model
correl
dmab
express
circul
repeat
administr
led
increas
dmab
express
kinet
period
day
reduct
nonhdlc
pool
sera
day
figur
construct
evalu
human
dmab
plasmid
engin
express
either
human
mous
fc
region
label
respect
design
evalu
effect
express
level
kinet
vivo
evalu
cell
show
dmab
express
level
ngml
figur
strong
express
also
confirm
cell
use
fluoresc
microscopi
intracellular
stain
antihuman
iggfluorescein
isothiocyan
fitc
western
blotbind
studi
demonstr
bind
recombin
human
mous
protein
express
level
kinet
analyz
vivo
wildtyp
nude
mice
figur
singl
intramuscular
administr
mg
plasmid
dna
reach
maximum
mean
ngml
protein
mab
day
nude
mice
wildtyp
mice
acut
immun
reaction
dmab
contain
human
fc
result
drop
dmab
express
day
maximum
express
observ
day
mean
around
ngml
mg
dose
result
human
dmab
studi
wildtyp
mice
demonstr
import
consid
intraspeci
differ
antibodi
evalu
may
impact
translat
model
reason
result
drop
express
human
dmab
interest
possibl
immunogen
factor
could
involv
investig
futur
studi
function
activ
sera
dmab
confirm
bind
western
blot
analysi
show
bind
recombin
mous
human
protein
figur
dmab
express
also
confirm
vivo
immunohistochemistri
analysi
mous
muscl
tissu
day
shown
figur
immunohistochemistri
use
immunostain
antihuman
igghorseradish
peroxidas
hrp
indic
posit
brown
mous
tibiali
anterior
muscl
section
compar
brown
control
muscl
section
h
e
stain
dmabtreat
control
group
show
sign
tissu
damag
confirm
express
dmab
lack
tissu
damag
caus
administr
perform
similarli
capac
lipid
reduct
wildtyp
nude
mice
figur
wildtyp
mice
signific
decreas
nonhdlc
detect
day
group
reduct
day
total
cholesterol
reduct
also
observ
decreas
day
compar
demonstr
better
reduct
nonhdlc
total
cholesterol
correl
superior
express
level
durat
circul
match
speci
nude
mice
signific
reduct
nonhdlc
day
speci
antibodi
human
mous
dmab
group
reduct
persist
final
endpoint
day
similar
reduct
total
cholesterol
persist
day
decreas
although
express
well
mous
human
dmab
perform
well
lipid
reduct
shortterm
studi
support
potenti
applic
human
fc
dmab
match
speci
set
individu
elev
ldlc
afflict
hereditari
famili
hypercholesterolemia
increas
risk
chd
ldlc
reduct
therapi
hmgcoa
reductas
inhibitor
statin
standard
treatment
reduc
risk
chd
intoler
musculoskelet
symptom
prevent
use
altern
therapi
need
gold
standard
reduc
high
ldlc
caus
advers
effect
inhibitor
emerg
potent
import
new
approach
reduc
ldlc
increas
hepat
clearanc
via
ldlr
sever
strategi
taken
inhibit
mab
achiev
recent
success
evolocumab
alirocumab
two
fdaapprov
recombin
mab
shown
signific
ldlc
reduct
variou
recombin
antibodi
investig
mice
lipidlow
capabl
zhang
et
al
develop
transgen
cholesteryl
ester
transfer
protein
cetp
ldlrhemi
mous
model
express
human
cetp
transgen
one
copi
ldlr
mimic
healthi
human
lipid
level
mice
hr
singl
intraven
administr
antibodi
mgkg
reduct
baselin
ldlc
serum
antibodi
level
mgml
correl
express
level
lipid
reduct
capabl
observ
dmab
even
signific
reduct
ldlc
higher
administ
recombin
antibodi
dose
mgkg
mgkg
chan
et
al
evalu
antibodi
wildtyp
mice
ldlrknockout
mice
observ
reduct
total
cholesterol
day
administr
wildtyp
mice
detect
chang
ldlrknockout
mice
anoth
group
examin
effect
antibodi
human
hyperlipidem
humhum
ldlr
mice
carbohydraterich
diet
antibodi
reduc
ldlc
prediet
level
within
hr
also
found
effect
cynomolgu
monkey
reduct
ldlc
day
singl
intraven
administr
recombin
mab
shown
success
major
limit
factor
use
high
cost
moreov
requir
frequent
dose
everi
week
use
recombin
antibodi
therapeut
develop
novel
approach
inhibit
use
dmab
technolog
dmab
sever
advantag
make
import
new
technolog
develop
proteinbas
therapeut
costeffect
eas
manufactur
stabil
requir
cold
chain
rapid
develop
engin
dmab
deliv
via
intramuscular
intraderm
rout
via
vivo
electropor
plasmid
dna
lowvoltag
electropor
lead
consist
intracellular
deliveri
inject
plasmid
dna
dmab
platform
shown
protect
efficaci
sever
viral
pathogen
includ
hiv
middl
east
respiratori
syndrom
mer
zika
among
other
current
evalu
immunotherapeut
cancer
studi
use
cellectra
vivo
electropor
devic
util
adapt
constant
current
electropor
system
measur
tissu
resist
adjust
real
time
prevent
tissu
damag
enhanc
dna
uptak
dna
deliveri
electropor
abl
allow
enhanc
gene
express
vivo
sever
impact
clinic
studi
perform
use
vivo
electropor
technolog
one
exampl
human
papilloma
viru
hpv
dna
vaccin
show
efficaci
phase
iib
clinic
trial
demonstr
robust
antigenspecif
cell
respons
well
induc
clearanc
hpv
viru
lesion
anoth
exampl
develop
zika
viru
dna
vaccin
report
new
england
journal
medicin
phase
clinic
trial
evalu
safeti
immunogen
dna
vaccin
healthi
adult
demonstr
develop
bind
neutral
antibodi
associ
protect
anim
model
studi
mous
dmab
capabl
express
day
wildtyp
mice
express
sever
month
demonstr
sever
dmab
antidengu
anitebola
ap
unpublish
data
immunoadhesin
studi
support
potenti
dmab
last
sever
month
administ
possibl
treatment
atherosclerot
cardiovascular
diseas
evalu
efficaci
dmab
platform
abil
express
antibodi
directli
vivo
exhibit
lipidlow
properti
mice
dmab
use
mousematch
backbon
found
express
least
week
vivo
reason
level
importantli
inhibit
observ
vivo
show
elev
liver
ldlr
express
day
treatment
singl
intramuscular
administr
dmab
mg
plasmid
dna
observ
reduct
analys
carri
mice
sera
use
vitro
clinic
chemistri
analyz
percent
chang
calcul
day
rel
control
mice
statist
differ
indic
rel
day
treatment
data
express
sem
n
statist
differ
measur
use
twoway
anova
test
p
p
p
ns
signific
nonhdlc
total
cholesterol
mous
human
antibodi
signific
reduct
nonhdlc
observ
earli
day
postadministr
wildtyp
nude
mice
compar
wildtyp
neg
control
reduct
day
group
human
mous
dmab
led
decreas
nonhdlc
reduct
total
cholesterol
day
wildtyp
mice
normocholesterolem
use
current
studi
difficult
observ
signific
decreas
ldl
level
mice
compar
transgen
hypercholesterolem
mice
futur
studi
transgen
hypercholesterolem
mice
import
evalu
dmab
conclus
result
demonstr
efficaci
highli
novel
dmab
reduc
nonhdlc
total
cholesterol
suggest
potenti
new
technolog
treatment
atherosclerot
cardiovascular
diseas
famili
hypercholesterolemia
patient
novel
dnaproduc
antibodybas
therapeut
could
valuabl
altern
method
therapi
treatment
hypercholesterolemia
cardiovascular
diseas
mous
hepatoma
human
cell
maintain
dmem
gibcolif
technolog
supplement
fetal
bovin
serum
fb
uml
penicillin
mgml
streptomycin
life
technolog
dmab
plasmid
design
encod
human
mous
mab
dmab
transgen
design
singl
open
read
frame
variabl
constant
heavi
chain
separ
variabl
constant
light
chain
cleavag
site
two
construct
develop
human
dmab
backbon
mous
dmab
backbon
dmab
transgen
flank
bamhi
xhoi
restrict
enzym
site
synthes
genscript
subclon
correspond
restrict
enzym
site
mammalian
express
vector
human
cmv
immediateearli
promot
vector
use
drive
express
antibodi
cell
transfect
dmab
plasmid
use
lipofectamin
ltx
reagent
follow
manufactur
protocol
briefli
cell
seed
plate
incub
c
incub
co
cell
transfect
mg
dmab
plasmid
confluenc
incub
maximum
hr
dmab
express
follow
transfect
analyz
western
blot
elisa
immunofluoresc
microscopi
bind
western
blot
analysi
perform
evalu
dmabbind
capabl
recombin
human
mous
protein
mg
run
precast
bistri
gel
invitrogen
nonreduc
condit
gel
transfer
immobilonfl
polyvinyliden
fluorid
pvdf
transfer
membran
millipor
membran
block
odyssey
block
buffer
licor
bioscienc
hr
stain
overnight
c
either
supernat
dmabtransfect
cell
serum
dmabtreat
mice
compar
control
sampl
membran
wash
pbst
pb
tween
subsequ
membran
stain
either
antihuman
antimous
igg
antibodi
licor
bioscienc
hr
room
temperatur
rt
wash
pbst
membran
scan
licor
odyssey
clx
imag
mg
total
sampl
protein
load
gel
run
describ
analysi
liver
lysat
ldlr
express
membran
stain
antimldlr
primari
antibodi
r
system
actin
stain
use
antiactin
primari
antibodi
abcam
antirabbit
igghrp
secondari
antibodi
dmab
human
backbon
quantifi
elisa
total
human
igg
elisa
maxisorp
plate
coat
mgwell
antihuman
iggfc
fragment
antibodi
bethyl
laboratori
overnight
c
plate
block
fb
pb
hr
rt
sampl
recombin
human
igg
standard
ad
plate
hr
rt
wash
plate
antihuman
iggfc
fragment
antibodyhrp
bethyl
laboratori
ad
hr
rt
sigmafast
opd
sigmaaldrich
substrat
solut
use
sampl
detect
optic
densiti
measur
nm
use
glomax
micropl
luminomet
promega
quantif
dmab
mous
backbon
cell
supernat
plate
coat
antimous
iggfc
fragment
antibodi
bethyl
laboratori
antimous
igghrp
invitrogen
use
detect
serum
sampl
dmab
mous
backbon
differenti
background
mous
igg
coat
elisa
plate
recombin
protein
purifi
recombin
mab
use
standard
quantit
elisa
data
express
sem
n
cell
transfect
dmab
use
lipofectamin
ltx
reagent
describ
hr
transfect
cell
wash
pb
fix
paraformaldehyd
min
rt
cell
wash
incub
antihuman
iggfitc
bethyl
laboratori
hr
wash
cell
stain
dapi
nuclear
stain
imag
evo
fl
imag
system
flow
cytometri
use
detect
ldlr
cell
transfect
control
dmab
plasmid
hr
posttransfect
cell
wash
fluorescenceactiv
cell
sort
fac
buffer
fb
pb
stain
antildlr
primari
antibodi
abcam
hr
c
follow
antirabbit
iggfitc
secondari
antibodi
abcam
hr
c
cell
wash
time
fac
buffer
fix
paraformaldehyd
cell
analyz
flow
cytomet
bd
bioscienc
immunohistochemistri
perform
wistar
institut
histotechnolog
facil
briefli
mous
anterior
tibiali
muscl
section
resect
embed
paraffin
paraffinembed
sampl
treat
antigen
retriev
reagent
deparaffin
slide
fix
aceton
wash
pb
follow
block
stain
section
antihuman
igg
antibodyhrp
evalu
dmab
carri
wildtyp
nude
mice
anim
experi
carri
accord
guidelin
nih
wistar
institut
institut
anim
care
use
committe
iacuc
mice
inject
plasmid
dna
tibiali
anterior
quadricep
muscl
vivo
electropor
perform
use
cellectra
adapt
constantcurr
ep
devic
inovio
pharmaceut
triangular
array
consist
solid
stainless
steel
electrod
use
deliv
squarewav
puls
two
constantcurr
puls
deliv
mspuls
separ
delay
puls
mice
given
either
mg
plasmid
dna
resuspend
water
plasmid
coformul
recombin
hyaluronidas
enhanc
intramuscular
distribut
maximum
ml
volum
use
inject
site
empti
vector
use
neg
control
dmab
blood
collect
submandibular
bleed
dmab
quantif
lipid
panel
analysi
sampl
collect
day
lipid
panel
analysi
carri
use
vitro
clinic
chemistri
analyz
mice
fast
hr
bled
submandibular
bleed
serum
sampl
collect
whole
blood
use
lipid
panel
analysi
mous
nonhdlc
level
calcul
subtract
hdlc
total
cholesterol
experiment
data
analyz
use
twoway
anova
test
differ
deem
signific
p
valu
graph
prepar
use
graphpad
prism
softwar
lh
employe
inovio
pharmaceut
receiv
salari
benefit
includ
ownership
stock
stock
option
dbw
disclos
grant
fund
industri
collabor
speak
honoraria
fee
stock
consult
servic
includ
serv
scientif
review
committe
advisori
board
remuner
includ
direct
payment
andor
stock
stock
option
km
report
receiv
grant
inovio
receiv
consult
fee
inovio
relat
dna
vaccin
develop
author
declar
compet
financi
interest
